Dopamine & Motivation

Also known as: ACTH 4-10, BDNF Spray, BDNF, Flow Spray

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro, MEHFPGP, 813 Da molecular weight) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s. The compound is derived from ACTH(4-10) — the 4-10 amino acid fragment of adrenocorticotropic hormone — with the addition of a Pro-Gly-Pro C-terminal tail that confers resistance to enzymatic degradation while preserving neurotropic activity. Critically, Semax retains the cognitive, neurotrophic, and neuroprotective effects of its ACTH parent while completely lacking the adrenal-stimulating hormonal activity. In other words, Semax works on the brain without activating the HPA axis or affecting cortisol production — a therapeutically ideal profile. Semax was patented in 1982 by Russian researchers and achieved regulatory approval in the Russian Federation in 2000, where it is prescribed at pharmacies for cerebrovascular disorders (ischemic stroke recovery), optic nerve disorders, minimal brain dysfunction in children (ADHD-like presentations), asthenia, and various cognitive complaints. It is available in two commercial strengths: 0.1% intranasal solution for cognitive-nootropic indications and 1% intranasal solution for stroke recovery and neurological deficits. In Western markets, Semax has never been submitted for FDA, EMA, or other major regulatory approval — a pattern common to Russian neuropeptides that lack patent protection and Western pharmaceutical sponsors. It circulates in US and European biohacking communities through research chemical peptide suppliers and is considered one of the most potent, best-tolerated nootropic compounds available. The pharmacology of Semax is genuinely notable and spans multiple neurological domains. At the molecular level, Semax elevates BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) expression in the brain, promotes dopaminergic and serotonergic signaling, potentiates endogenous enkephalin activity, and upregulates expression of neuroprotective genes. At the clinical level, it produces cognitive enhancement (attention, memory, executive function), mood elevation, stress tolerance, neuroprotection during ischemia, and accelerated recovery from neurological injury. Russian clinical trials in acute ischemic stroke — the best-documented Semax indication — show meaningful improvements in functional recovery when Semax is administered within 6-24 hours of stroke onset, likely through direct neuroprotection plus enhanced neurogenesis during recovery. The stroke literature is the only domain where Semax has truly rigorous clinical trial evidence (Gusev et al., 2005). In the biohacking and cognitive enhancement community, Semax has achieved a reputation as the "premier Russian nootropic" — often positioned alongside Selank, Noopept, Modafinil, and racetams in the advanced cognitive stack. Users typically report improvements in focus, working memory, verbal fluency, motivation, stress tolerance, and overall cognitive throughput. The effects are often described as "clean" — producing alertness and engagement without the jitters of stimulants, without the emotional blunting of SSRIs, and without the sedation of anxiolytics. Dose-response is relatively modest (300-900 mcg daily typical), onset is rapid (15-30 minutes after intranasal administration), and effects last several hours per dose. Chronic use over weeks produces accumulating cognitive and mood benefits that appear to outlast plasma presence. This entry covers Semax pharmacology, the genuinely rigorous Russian stroke evidence base, the more speculative cognitive enhancement applications, protocol considerations, and safety profile. It should be read as an educational reference — Semax is not FDA-approved, is distributed through gray-market channels with variable quality, and anyone considering use should obtain reliable product, start conservatively, and have realistic expectations. Cross-reference with Selank, DSIP, and Epithalon for Russian peptide context, and with Noopept, Piracetam, and Modafinil for broader nootropic comparisons.

Also known as: NASA-Semax, N-Acetyl Semax

Acetylated form of Semax peptide with improved stability and potency, used as a nasal spray for cognitive enhancement and neuroprotection.

Also known as: TP-7, Selank Spray

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro, 750 Da molecular weight) developed in the 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences as a synthetic analog of tuftsin — an immunomodulatory tetrapeptide (Thr-Lys-Pro-Arg) that is naturally cleaved from the Fc region of immunoglobulin G. The original tuftsin molecule has well-documented immunomodulatory and neurotropic effects but is rapidly degraded by peptidases in plasma, limiting its therapeutic utility. Selank adds a Pro-Gly-Pro tail to the tuftsin sequence, which confers resistance to enzymatic degradation while preserving pharmacological activity. In Russia, Selank has been approved since 2004 for the treatment of generalized anxiety disorder (GAD) and is available by prescription at pharmacies across the Russian Federation and several neighboring countries. It is marketed as a 0.15% intranasal solution under the brand name "Selank" (╨í╨╡╨╗╨░╨╜╨║) by Peptogen, a Moscow-based pharmaceutical company. In Western markets, Selank has never been submitted for FDA, EMA, or other major regulatory approval — not because of unfavorable data, but because the commercial pharmaceutical industry has no mechanism to profit from a peptide with an expired patent and no Western development sponsor. As a result, Selank circulates in the biohacking and peptide-curious community primarily as a "research chemical" through specialty peptide suppliers, where it is sold in intranasal spray or injectable formulations. The pharmacological profile of Selank is distinctive among anxiolytics. Unlike benzodiazepines, it does NOT cause sedation, cognitive dulling, tolerance, dependence, or withdrawal. Unlike SSRIs, it has rapid onset (within 30-60 minutes of intranasal administration) and effects that outlast plasma presence. Unlike buspirone, it does not require weeks of chronic dosing to manifest effects. The compound appears to work through modulation of multiple neurotransmitter systems simultaneously — GABAergic, serotonergic, dopaminergic, and endogenous opioid — producing what the Russian clinical literature describes as an "anxiolytic + nootropic" profile: the user feels calmer but also more mentally engaged, not sedated. This unusual combination has driven substantial interest in Western biohacking circles as an alternative or adjunct to conventional anxiety pharmacology. Selank has been studied in Russian clinical populations for over two decades with a consistent efficacy and safety pattern across roughly 30-50 published clinical papers. The evidence base is real but has important limitations: most trials are Russian-language, published in Russian journals, with small sample sizes (often 30-100 patients), and use Russian psychiatric rating scales rather than the validated Western instruments (GAD-7, HAM-A, Beck Anxiety Inventory) that would facilitate cross-validation. Western meta-analyses and systematic reviews are essentially nonexistent. The Russian regulatory approval is real and meaningful — Russian drug regulation, while different from FDA standards, does require efficacy and safety evidence — but it does not automatically translate to confidence in Western evidence-based medicine frameworks. For the biohacking community, Selank's appeal is the combination of (1) rapid-acting anxiolysis without sedation, (2) cognitive enhancement rather than dulling, (3) favorable safety profile across decades of Russian use, (4) non-addictive, non-dependence-producing pharmacology, and (5) intranasal delivery that is simple and needle-free. Its limitations are (1) thin Western evidence base, (2) variable quality from research chemical suppliers, (3) lack of FDA regulation or oversight, (4) modest effect magnitude in some users relative to expectations, and (5) cost relative to generic anxiety pharmacology. This entry covers the pharmacology, clinical evidence, practical use considerations, and honest framing of the evidence gaps. Cross-reference with Semax, DSIP, and Epithalon for a complete picture of the Russian research peptide landscape.

Bromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten. Chemically it is N-(2-adamantyl)-N-(para-bromophenyl)amine, an adamantane derivative structurally related to amantadine and memantine but pharmacologically distinct from both. What makes Bromantane unusual and clinically interesting is that it acts simultaneously as a mild dopamine reuptake inhibitor and as an activator of tyrosine hydroxylase and aromatic L-amino acid decarboxylase gene expression in mesolimbic and mesocortical dopamine neurons, producing a gentle upregulation of endogenous dopamine synthesis rather than the forceful synaptic dopamine release characteristic of amphetamines or methylphenidate; alongside this dopaminergic effect it promotes neurosteroid synthesis particularly of allopregnanolone and related GABA-A positive modulators, which is thought to underlie its anxiolytic rather than anxiogenic profile and distinguishes it from conventional stimulants that typically produce dose-dependent anxiety. The clinical positioning in Russia has been for neurasthenia, asthenic depression, chronic fatigue states, post-infectious fatigue, and adaptation support during physical and cognitive stress, with multiple placebo-controlled and active-comparator trials published in Russian and occasionally English literature reporting benefits across fatigue, attention, mood, and sleep quality scales at daily doses typically in the 50-100 mg range for 2-6 week courses. Outside Russia Bromantane has never been approved for clinical use, is not controlled under most Western drug schedules because it predates modern scheduling and does not fit amphetamine or modafinil frameworks cleanly, and circulates primarily as a research chemical or grey-market nootropic with substantial user interest in biohacker communities. Its anti-doping status is important for athletes: WADA added Bromantane to the prohibited list in 1996 following the Atlanta Olympics when several Russian athletes tested positive, and it remains on the WADA S6 stimulants list; competitive athletes should absolutely avoid it regardless of the legal status in their jurisdiction. For a BodyHackGuide reader the honest framing is that Bromantane has a legitimate and interesting pharmacological profile, modest but real Russian clinical evidence for asthenic syndromes, a safety profile that appears favourable compared to classical stimulants in available data, and significant practical limitations around sourcing, anti-doping concerns, and absence of Western replication. Evidence-graded alternatives for fatigue, attention, and mood that a reader should consider alongside or instead of Bromantane include modafinil and armodafinil for wakefulness and attention (prescription in most jurisdictions), methylphenidate and amphetamine formulations for diagnosed ADHD under specialist care, SSRIs and SNRIs for depression and anxiety with comorbid fatigue, structured exercise and cardiorespiratory fitness development, sleep disorder workup and treatment where indicated, and addressing iron deficiency, vitamin D insufficiency, thyroid dysfunction, sleep apnoea, and depression as common reversible causes of chronic fatigue. Internal cross-links include noopept, selank, semax, bpc-157, modafinil, methylene-blue, nad, and sulbutiamine where those entries exist.

Sulbutiamine (chemical name: isobutyryl thiamine disulfide; trade names include Arcalion, Enerion, Bisibutiamine) is a lipophilic synthetic derivative of vitamin B1 (thiamine), developed in Japan in the 1960s by Sankyo Company chemists who were seeking thiamine analogs with enhanced absorption and tissue penetration — particularly brain penetration. Structurally, sulbutiamine is a thiamine disulfide dimer in which two thiamine-derived moieties are linked by a disulfide bond and esterified with isobutyryl groups. This design makes sulbutiamine considerably more lipophilic than water-soluble thiamine hydrochloride, allowing it to cross lipid membranes (including the blood-brain barrier) more effectively than the parent vitamin. Once inside cells, sulbutiamine is reduced and hydrolysed to yield two molecules of thiamine, which then participate in normal thiamine biochemistry as thiamine pyrophosphate (TPP) — the active cofactor for pyruvate dehydrogenase, α-ketoglutarate dehydrogenase, branched-chain α-keto acid dehydrogenase, and transketolase. Sulbutiamine occupies an unusual regulatory position. It is an approved prescription medicine in France, several other European countries, parts of Asia, and various emerging markets, where it is indicated for treating asthenia (fatigue states) — a clinical concept that encompasses a range of fatigue syndromes, typically at doses of 400-600 mg/day. The French brand Arcalion is the most widely recognised form. In the United States, sulbutiamine is not FDA-approved as a drug and is not recognised as a dietary supplement under DSHEA, but it is not scheduled and is widely sold online as a nootropic/cognitive enhancer in powder and capsule form. In the United Kingdom, its status is ambiguous following the Psychoactive Substances Act 2016. In other jurisdictions, the legal status varies and users should verify locally before purchasing. The compound's appeal rests on four overlapping claims: (1) it may improve cognitive performance, particularly attention and memory, especially in the context of fatigue or mild asthenia; (2) it may reduce subjective fatigue; (3) it may have mild pro-cholinergic and pro-dopaminergic effects in addition to replenishing thiamine cofactor availability; and (4) it is generally well tolerated at therapeutic doses. Each of these claims has some experimental support, primarily from French clinical studies of asthenia and from a handful of PubMed-indexed rodent and human studies. The evidence base is larger than for many nootropic compounds but still modest compared with mainstream psychiatric or neurological medicines. It is important to place sulbutiamine honestly in the therapeutic landscape. For frank thiamine deficiency (beriberi, Wernicke's encephalopathy, dry or wet beriberi), the standard of care is intravenous or intramuscular thiamine hydrochloride at high doses — not sulbutiamine. Wernicke-Korsakoff syndrome requires emergency parenteral thiamine administration and is not an indication for oral sulbutiamine. For generalised fatigue without thiamine deficiency — the complaint most commonly prompting self-administration of sulbutiamine — the evidence-based approach is to evaluate for underlying causes (sleep disorders, depression, anaemia, thyroid dysfunction, chronic infection, autoimmune disease, cardiovascular disease, medication effects, substance use, psychosocial stressors) and treat the cause. Empiric treatment of fatigue with an oral thiamine derivative is, at best, a tertiary option after evidence-based causes have been excluded. For depression, evidence-based treatments include SSRIs, SNRIs, cognitive-behavioural therapy, and increasingly, rapid-acting agents like ketamine and esketamine for treatment-resistant cases — sulbutiamine is not a substitute for any of these. Where sulbutiamine may legitimately have a role is in the following contexts: (1) as an adjunct for patients with genuine asthenia in jurisdictions where it is approved and prescribed by a physician; (2) as an occasional cognitive/fatigue support supplement for healthy adults who have exhausted sleep, nutrition, and exercise optimisation; (3) potentially in the context of chronic fatigue syndromes (ME/CFS) or post-infectious fatigue, where evidence is preliminary but biologically plausible; and (4) in populations at risk for mild thiamine insufficiency — chronic alcohol use (though these patients need parenteral thiamine acutely), bariatric post-surgical patients, and some dietary restriction contexts. Sulbutiamine is often discussed alongside other nootropic B-vitamin derivatives such as benfotiamine (a different lipid-soluble thiamine derivative used primarily for diabetic neuropathy) and allithiamine (a related S-allyl thiamine found in garlic). Compared with benfotiamine, sulbutiamine is thought to have greater CNS penetration and more pronounced central cognitive effects, while benfotiamine is thought to produce higher peripheral thiamine levels with more benefit for diabetic neuropathy. These comparisons are mechanistic rather than head-to-head trial-based. Users interested in general cognitive enhancement may also see sulbutiamine discussed alongside noopept, selank, semax, piracetam, and choline sources like alpha-GPC and CDP-choline. As with any compound in the unregulated-supplement-or-prescription grey zone, sourcing matters. Prescription Arcalion obtained from a French or European pharmacy is a quality-controlled pharmaceutical product; sulbutiamine powder from an online supplement vendor may or may not be what the label claims. Users should favour either prescription supply or vendors providing third-party certificates of analysis (HPLC purity testing).

Also known as: Provigil, Alertec, Modalert, Modvigil, Modawake, 2-((diphenylmethyl)sulfinyl)acetamide, CRL-40476

Modafinil is a prescription wakefulness-promoting agent approved by the US Food and Drug Administration in December 1998 under the brand name Provigil (Cephalon, now Teva) for the treatment of excessive daytime sleepiness associated with narcolepsy, shift work sleep disorder, and as an adjunct to continuous positive airway pressure therapy in obstructive sleep apnea. It is a racemic mixture of R- and S-enantiomers; the R-enantiomer (armodafinil, brand name Nuvigil) was approved separately in 2007 as a longer-acting alternative. Modafinil became a Schedule IV controlled substance in the United States in 1999, reflecting a low but non-zero abuse potential that is substantially below that of amphetamines and classical stimulants. The compound is structurally unrelated to amphetamines, methylphenidate, and other stimulant classes — it is a diphenylmethylsulfinyl acetamide with a distinct pharmacology that produces wakefulness and cognitive effects without the catecholamine surge, appetite suppression, and cardiovascular profile of traditional stimulants. Modafinil's approved medical use base is narrow, but its off-label use is enormous. Physicians prescribe it off-label for ADHD (particularly in patients who do not tolerate or respond to stimulants), fatigue in multiple sclerosis and other neurologic conditions, cancer-related fatigue, depression augmentation (particularly for residual fatigue and cognitive symptoms), post-concussion cognitive dysfunction, jet lag, and age-related cognitive decline. Off-label and non-medical use as a cognitive enhancer — among students preparing for exams, professionals working long hours, military personnel during sustained operations, and the general nootropic community — has made modafinil one of the most-discussed cognitive enhancement compounds in both academic and lay media. The evidence base is substantial for approved indications and mixed for off-label use, with meta-analyses and systematic reviews documenting meaningful cognitive benefits in sleep-deprived users and healthy users performing complex cognitive tasks, alongside more modest or inconsistent effects on simple cognitive measures in rested users. Its safety profile across 25+ years of clinical use is generally favorable, though rare serious adverse events including Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS syndrome (drug reaction with eosinophilia and systemic symptoms) require specific attention. This entry covers modafinil's mechanism of action and the ongoing uncertainty about which of its multiple pharmacologic effects drives wakefulness; the clinical evidence base for approved indications including narcolepsy, shift work disorder, and OSA; the off-label cognitive enhancement literature with its well-known heterogeneity between sleep-deprived and rested subjects; the side effect profile including common, serious, and rare adverse effects; the practical dosing conventions used in medical and non-medical contexts; its interactions with hormonal contraception and CYP450 substrates; contraindications based on cardiovascular, hepatic, and psychiatric history; how modafinil compares to and stacks with other nootropic compounds like Noopept, Piracetam, Sulbutiamine, Bromantane, Selank, Semax, Methylene Blue, NAD+, L-Theanine, and L-Tyrosine; and what responsible use looks like for someone considering modafinil for either medical or cognitive enhancement purposes. Modafinil remains the single most clinically validated cognitive enhancement compound available, with a body of evidence, safety data, and regulatory oversight that no research-chemical nootropic can match. For users who need demonstrably effective wakefulness promotion for legitimate medical reasons, it is a first-line option. For users considering it for cognitive enhancement, it is a serious drug with real effects and real side effects that deserves a serious evaluation rather than casual experimentation.

Phenylpiracetam is a Russian-developed phenyl derivative of piracetam with a dramatically higher potency and stimulant profile. Approved in Russia as Phenotropil/Carphedon for cognitive impairment and stroke recovery. Banned by WADA as a performance-improving drug due to its stimulant effects, significantly improving physical endurance in addition to cognition. One of the most potent and sought-after racetam family members.

Also known as: Mucuna, Velvet Bean, Kapikacchu, Atmagupta, Kauchni, Kaunch, Cowitch, Cowhage, Itching Powder, Kiwach

Mucuna pruriens — known as velvet bean in English, Kapikacchu (αñòαñ¬αñ┐αñòαñÜαÑìαñ¢αÑé) or Atmagupta in Sanskrit, Kauchni or Kaunch in Hindi, and cowitch or cowhage in older Western materia medica — is one of the most pharmacologically unusual legumes on earth and one of the very few medicinal plants whose primary active constituent is a well-characterized pharmaceutical drug rather than a complex phytochemical mixture. The seeds of Mucuna pruriens naturally contain 3-7% levodopa (L-DOPA, L-3,4-dihydroxyphenylalanine) by dry weight — the same molecule that has been the cornerstone of Parkinson's disease pharmacotherapy since the 1960s — along with smaller amounts of serotonin, 5-hydroxytryptophan (5-HTP), nicotine, bufotenine, N,N-dimethyltryptamine (DMT), beta-carboline alkaloids, and several minor alkaloids including mucunine, mucunadine, mucuadinine, prurienine, and prurieninine. This notable phytochemical profile makes Mucuna a genuine "natural pharmacy" for the dopaminergic system — not in the usually hand-wavy sense that some adaptogenic herbs are described, but in the literal sense that it contains the actual drug molecule used clinically. The plant is a climbing tropical legume with distinctive seed pods covered in fine, barbed trichomes (hairs) that produce intense contact dermatitis on human skin — the Hindi name Kauchni and the English "itching powder" both reference this property, and the trichomes contain a serotonin-releasing protein called mucunain that causes the itch response. Processed seeds, with the trichomes removed, have been used medicinally for over 4,000 years in Ayurveda, primarily as a male reproductive tonic (Vajikarana rasayana), for the treatment of parkinsonian symptoms called Kampavata (literally "shaking wind" — a disease description remarkably similar to what we now call Parkinson's disease), and for a broad spectrum of neurological, sexual, and metabolic indications. Modern clinical research on Mucuna pruriens has taken two distinct directions. The first, and by far the most important, is its use as a natural source of levodopa for Parkinson's disease, either in resource-limited settings where pharmaceutical levodopa-carbidopa is expensive or unavailable, or as an adjunct in wealthier settings to address specific limitations of standard therapy. Multiple controlled trials — most notably Katzenschlager and colleagues' 2004 study at the Queen Square Institute of Neurology (PMID 15585799) and Manyam and colleagues' 2004 HP-200 formulation trial (PMID 15099104) — have demonstrated that Mucuna pruriens seed powder produces motor improvements in Parkinson's patients comparable to standard levodopa-carbidopa, with some pharmacokinetic and tolerability advantages including faster onset, longer duration of effect, and reduced peak-dose dyskinesia in some patient populations. The mechanism for these advantages is not fully understood but may involve the minor alkaloids acting as peripheral decarboxylase inhibitors (mimicking the carbidopa component), along with a more physiological release profile from the complex plant matrix. The second research direction is Mucuna's role as a male reproductive and stress-modulating adaptogen. Controlled trials in infertile men — Shukla and colleagues 2007 (PMID 17196359), Ahmad and colleagues 2008 (PMID 18973898) — have demonstrated improvements in sperm concentration, motility, and morphology along with reductions in stress-related parameters (cortisol, lipid peroxidation), which is consistent with the traditional Vajikarana use. The mechanism for reproductive effects appears to involve dopaminergic stimulation of hypothalamic-pituitary-gonadal axis function, reduction of oxidative stress in testicular tissue, and modulation of cortisol responses to stress. Modern supplement markets offer Mucuna pruriens in several forms: whole seed powder (typically 1-3% L-DOPA by weight), standardized extracts to 15%, 20%, 40%, or 99% L-DOPA content, and specialized formulations like HP-200 (an early-stage clinical formulation studied in Parkinson's disease). Many consumers and casual nootropic users encounter Mucuna as a low-dose L-DOPA supplement marketed for mood, motivation, libido, and dream vividness — indications that are biologically plausible but less rigorously studied than the Parkinson's and fertility applications. The classical Ayurvedic preparation uses whole, processed, roasted seeds ground into a powder and taken with warm milk and ghee, typically at doses of 3-9 grams daily; the L-DOPA dose in this preparation is quite modest (roughly 50-200 mg) and produces gentle, sustained dopaminergic support rather than the acute pharmaceutical-level effect of concentrated extracts. High-concentration extracts (20-99% L-DOPA) should be treated with the same respect as pharmaceutical levodopa — they are not casual supplements, they have meaningful side effects and drug interactions, and they are not appropriate for long-term use in healthy individuals without a specific clinical indication. For Parkinson's disease, use of Mucuna should only occur under neurology supervision and as part of a coordinated treatment plan. For general wellness and reproductive health in otherwise healthy adults, low to moderate doses of whole-seed or lightly standardized preparations (1-5% L-DOPA) are the appropriate starting point.

Also known as: Tyrosine, L-Tyr, 2-Amino-3-(4-hydroxyphenyl)propanoic acid, NALT, N-Acetyl-L-Tyrosine

L-Tyrosine is a non-essential aromatic amino acid and the direct biosynthetic precursor to the catecholamine neurotransmitters dopamine, norepinephrine, and epinephrine. Unlike "essential" amino acids that must be obtained from diet, tyrosine can be synthesized in the human body from phenylalanine via the enzyme phenylalanine hydroxylase (PAH) — the same enzyme that is deficient in the genetic disorder phenylketonuria (PKU), which is why PKU patients require dietary tyrosine supplementation as part of their medical management. Dietary sources of tyrosine include cheese (the amino acid was originally isolated from casein, and its name derives from the Greek tyros meaning "cheese"), chicken, fish, eggs, nuts, seeds, soy products, and dairy. Typical Western diets provide 1-5 g of tyrosine daily from food sources, which is adequate for general protein synthesis and catecholamine turnover under normal conditions. The cognitive performance use case for supplemental tyrosine rests on a specific pharmacologic logic: during periods of intense acute stress — cold exposure, sleep deprivation, sustained mental workload, combat operations — catecholamine synthesis in the brain can become rate-limited by tyrosine availability at the tyrosine hydroxylase step (the rate-limiting enzyme in catecholamine biosynthesis). Under these conditions, supplemental tyrosine at doses of 100-150 mg/kg (roughly 7-12 g for a 70 kg adult in the original research context, though practical doses are typically lower at 500-2000 mg) can raise brain tyrosine levels, accelerate catecholamine synthesis, and support cognitive performance that would otherwise degrade under stress. The seminal research establishing this cognitive-performance effect came from US Army and academic laboratories in the 1980s-1990s, with Banderet and Lieberman's 1989 work at the US Army Research Institute of Environmental Medicine demonstrating that tyrosine supplementation protected cognitive performance in subjects exposed to cold and altitude stress (PMID 2736402). Subsequent research extended these findings to sleep deprivation, combat operational stress, cognitively demanding military scenarios, and laboratory stress paradigms. A body of 30+ studies now documents tyrosine's cognitive protective effects under stress conditions, with a reasonably consistent finding: tyrosine provides modest but real cognitive performance protection during demanding conditions while producing minimal effects in rested, non-stressed users. The practical implication is that tyrosine is a niche cognitive enhancer rather than a general nootropic — it matters for specific situations (sleep-deprived work, cold exposure, high-stress cognitive challenges) and matters less for routine rested cognitive function. This entry covers tyrosine's mechanism of action as a catecholamine precursor and the pharmacologic logic of precursor loading; the clinical and military research evidence base for cognitive performance under stress including the Banderet-Lieberman and subsequent studies; the distinction between L-tyrosine and N-acetyl-L-tyrosine (NALT) and their relative bioavailability claims; the side effect profile including rare effects on thyroid function, blood pressure, and melanin synthesis; dosing conventions for acute pre-stress loading versus chronic daily supplementation; contraindications including MAO inhibitor use, active melanoma, and hyperthyroidism; and how tyrosine integrates into stacks with other cognitive enhancement and performance compounds including Modafinil, Piracetam, Noopept, Sulbutiamine, L-Theanine, Bromantane, Selank, and Semax. Tyrosine represents a well-understood, evidence-supported, low-risk cognitive performance intervention for specific stress-related applications — one of the few nootropic supplements with multiple rigorous randomized controlled trials supporting its use.

Also known as: PNB-0408

Dihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University. It is considered one of the most potent cognitive enhancers ever tested in animal models — reportedly 7 orders of magnitude more potent than BDNF at improving cognitive performance in rodent Alzheimer's models. Exclusively used by the research and biohacking community with no human clinical trial data available.

Also known as: MB, MB Vape, Methylene Blue Vape

Methylene blue (methylthioninium chloride) is a phenothiazine dye with a 150-year pharmacology record. It was the first fully synthetic drug ever used in medicine (Ehrlich, 1891 for malaria) and remains on the WHO Model List of Essential Medicines as the first-line treatment for acquired methemoglobinemia. In the last decade it has re-emerged in biohacking circles because low doses (~0.5 to 4 mg/kg) act as an alternative mitochondrial electron carrier, bypassing damage at Complex I/III of the respiratory chain and boosting cytochrome c oxidase activity (Atamna et al., 2008). The molecule has an auto-oxidizing redox cycle: reduced leucomethylene blue donates electrons to cytochrome c, then the oxidized form accepts electrons from NADH, effectively forming a "shunt" around dysfunctional mitochondrial complexes. This is why low-dose MB improves cerebral oxygen consumption and memory performance in humans, while high doses paradoxically inhibit the same system — the dose-response curve is hormetic and inverted-U, one of the most-cited nootropic examples in the field. There are two entirely different use cases for methylene blue, and collapsing them is the most common cause of harm: Medical methemoglobinemia rescue (1-2 mg/kg IV): Life-saving antidote delivered by clinicians for nitrate/nitrite/benzocaine/dapsone poisoning. Non-negotiable pharmaceutical-grade material, hospital setting. Nootropic/mitochondrial microdosing (0.5-4 mg oral per day): Off-label self-experimentation. Requires USP pharmaceutical-grade only — not the industrial textile dye sold on aquarium or lab-chemistry sites, which contains arsenic, cadmium, mercury, and other heavy metals above safe intake thresholds. If a vendor cannot produce a third-party Certificate of Analysis showing USP purity (>99%) with heavy-metal testing, it is not safe for ingestion at any dose. See our Vendor COA Guide and Methylene Blue Complete Guide for sourcing protocol.

Also known as: 1,3,7,9-tetramethyluric acid, TeaCrine, 1,3,7,9-tetramethyl-purine-2,6,8-trione

Theacrine (1,3,7,9-tetramethyluric acid) is a purine alkaloid structurally related to caffeine, found naturally in Camellia assamica var. kucha — a tea cultivar grown in southern China and northern Vietnam — and in smaller amounts in Cupuaçu (Theobroma grandiflorum) seeds. It shares caffeine's xanthine backbone but carries an extra methyl group at the 9-position and a 2,6,8-trione oxidation pattern, giving it pharmacology that overlaps caffeine's adenosine-receptor antagonism while diverging in dopaminergic tone and tolerance development. The most widely studied form in human trials is the patented ingredient TeaCrine, a ≥98% pure synthetic equivalent used in most commercial nootropic and pre-workout formulas. The practical appeal of theacrine in community use rests on three observations: first, healthy adults taking 200-300 mg daily report stimulation subjectively comparable to 150-200 mg caffeine — but with less jitter, less heart-rate elevation, and a slower onset (~60-90 minutes) that many users describe as "smoother" than caffeine's 20-40 minute peak. Second, an 8-week daily-dosing study (Taylor 2016, PMID 27335344) found no meaningful development of tolerance at 200-300 mg/day, no withdrawal signs on cessation, and no shifts in resting heart rate, blood pressure, liver enzymes, or complete blood count — a tolerance profile that genuinely differs from caffeine, where habitual use produces documented receptor upregulation and dependence within 1-2 weeks. Third, co-administration with caffeine produces synergy: pharmacokinetic data (He 2017, PMID 28356193) show caffeine roughly doubles theacrine plasma exposure (AUC), likely by slowing hepatic clearance, so 125 mg theacrine + 150 mg caffeine often outperforms either compound alone for perceived focus and endurance. Mechanism is not identical to caffeine. Like caffeine, theacrine antagonizes adenosine A1 and A2A receptors (the primary driver of wakefulness and reduced perception of effort), but rodent models (Feduccia 2012, PMID 22771692) additionally show dose-dependent increases in nucleus accumbens dopamine and locomotor activation that are blocked by both adenosine and dopamine-D1 antagonists — suggesting a dual adenosinergic-dopaminergic mechanism that caffeine does not fully replicate. This may explain the "motivation" quality users report and the absence of downregulation: chronic adenosine blockade alone should produce tolerance, but the concurrent dopaminergic signal appears to counterbalance receptor adaptation over an 8-week horizon. Human clinical data are limited but consistent. A double-blind crossover in habitual caffeine users (Ziegenfuss 2017, PMID 28280478) showed 300 mg theacrine improved reaction-time Bond-Lader alertness scores without the jitter-axis elevation that 150 mg caffeine produced in the same subjects. A separate 8-week safety and efficacy trial in 60 adults (Kuhman 2015, PMID 26569270) reported significant improvements in self-rated energy, focus, and concentration versus placebo at 200 and 300 mg/day with no adverse clinical findings. Community-tier evidence (r/Nootropics, forum writeups spanning 2015-2024) tends to converge on 100-200 mg as a mild-stim daily baseline, 250-300 mg for pre-workout or high-focus sessions, and 150 mg + 100 mg caffeine as a common synergy stack. Most users who transition from pure caffeine report similar energy with substantially less afternoon "crash" and easier sleep onset if taken before 2 PM. Practical considerations: theacrine is sold as a food-supplement ingredient in the US, EU, Australia, and most of Asia. It is NOT a controlled substance, not a prescription drug, and has no abuse liability signal in animal models. Quality matters — the vast majority of peer-reviewed human data used TeaCrine, a standardized ≥98% pure ingredient; some generic "theacrine" bulk powder has been found to be underdosed or contaminated with caffeine (independent COA testing, 2019-2021). Look for products that explicitly cite the TeaCrine trademark and provide a certificate of analysis. Theacrine is often stacked with L-theanine (100-200 mg) for an anxiolytic counterweight, with alpha-GPC (300 mg) for cholinergic contrast, and with dynamine (methylliberine, a faster-acting but shorter-duration analog) for a biphasic energy curve. It is not recommended for pregnancy, breastfeeding, uncontrolled hypertension, or anyone on MAOIs. The safety window at studied doses is wide, but the long-term profile beyond 8 weeks remains formally uncharacterized — community experience over 2-3 years of daily use suggests it holds up, but this is self-report data.

Also known as: 1,3,7-trimethylxanthine, Methyltheobromine, Trimethylxanthine, Theine, Guaranine, Mateine, Caffeine anhydrous, Caffeine citrate

Caffeine (1,3,7-trimethylxanthine) is a natural methylxanthine alkaloid found in the seeds, fruits, leaves, and bark of over 60 plant species — most notably Coffea (coffee), Camellia sinensis (tea), Theobroma cacao (cacao), Paullinia cupana (guaraná), Ilex paraguariensis (yerba mate), and Cola acuminata (kola nut). It is the world's most widely consumed psychoactive substance, with an estimated 80-90% of the global adult population consuming caffeine regularly — primarily through coffee, tea, cocoa, soft drinks, and energy drinks. Caffeine is the reference compound in pharmacology for adenosine receptor antagonism and one of the most comprehensively studied drugs in human history, with over 50,000 published studies covering its pharmacokinetics, pharmacodynamics, cognitive effects, cardiovascular impact, exercise performance, sleep effects, metabolic effects, addiction profile, and clinical applications. Pharmacologically, caffeine is a non-selective adenosine receptor antagonist — it binds and blocks adenosine A1, A2A, A2B, and A3 receptors throughout the body, with particularly important effects in the central nervous system (A1 and A2A antagonism in striatum, cortex, and sleep-regulating nuclei), heart (A1 antagonism contributing to mild tachycardia), adipose tissue (A1 antagonism promoting lipolysis), and airways (A2B antagonism contributing to mild bronchodilation). Adenosine is an endogenous signaling molecule that accumulates during wakefulness and neural activity, promoting sleepiness and reducing arousal through these receptor systems — caffeine works by blocking adenosine's sleep-promoting and fatigue-signaling effects, producing the familiar alerting, arousal, and performance-improving effects. Beyond adenosine receptor antagonism, caffeine at higher doses (typically >500mg) has additional pharmacologic actions: phosphodiesterase inhibition (modest), intracellular calcium mobilization via ryanodine receptors, and GABA-A receptor modulation — but these higher-dose mechanisms are not primary at typical consumption levels. Caffeine pharmacokinetics are remarkably variable between individuals, primarily reflecting genetic variation in the hepatic cytochrome P450 enzyme CYP1A2, which metabolizes ~95% of ingested caffeine. The **CYP1A2*1F polymorphism (rs762551) divides the population into "fast metabolizers" (AA genotype, ~40% of caffeine more rapidly cleared) and "slow metabolizers" (CC genotype, substantially slower clearance), with heterozygotes (AC) intermediate. This genetic variation produces notable differences in plasma half-life: 3-5 hours in fast metabolizers, 5-8 hours in intermediates, and up to 10-15 hours in slow metabolizers. The same 200mg caffeine dose can produce very different durations of effect — and very different sleep impacts from afternoon coffee — depending on CYP1A2 genotype. Additional modulators: oral contraceptives reduce caffeine clearance by ~40% (effectively doubling half-life), pregnancy reduces clearance by 50-60% in third trimester, smoking induces CYP1A2 and increases clearance by 30-50% (so smokers often report paradoxically shorter caffeine effects), liver disease prolongs half-life, and various medications (fluvoxamine, ciprofloxacin, cimetidine) inhibit CYP1A2 and prolong caffeine effects substantially. Understanding one's own caffeine pharmacokinetics — through genetic testing, self-observation of sleep effects from afternoon caffeine, and awareness of life-stage changes — is key to optimal caffeine use. Clinical applications and evidence base span notable breadth: (1) Cognitive performance and alertness — caffeine 40-200mg reliably improves reaction time, sustained attention, vigilance, and cognitive performance under fatigue (Smith 2002 meta-analysis, Lorist & Tops 2003). (2) Exercise performance — caffeine 3-6 mg/kg ingested ~60 minutes before exercise reliably improves endurance performance by 2-5% (Grgic et al. 2020 umbrella review), improves muscular endurance and some aspects of power output, and is classified by WADA as monitored but not banned at current consumption levels (though it was banned 1984-2004). (3) Headache treatment — caffeine potentiates analgesic effects of acetaminophen and aspirin (the basis for combinations like Excedrin); is first-line for post-dural puncture headache at IV doses; and improves many tension and migraine headaches. (4) Neonatal apnea of prematurity — IV caffeine citrate is standard-of-care treatment, with the landmark CAP trial (Schmidt 2006, 2012) establishing long-term developmental benefits. (5) Asthma and respiratory conditions — caffeine has mild bronchodilator effects; not a replacement for β2-agonists but some supplementary role. (6) Weight management — caffeine modestly increases energy expenditure and fat oxidation, though weight loss effects of caffeine alone are clinically modest. (7) Parkinson disease prevention — strong epidemiological evidence (Ross 2000, Palacios 2012) that lifetime coffee/caffeine consumption is associated with reduced Parkinson disease risk. (8) Type 2 diabetes prevention — strong epidemiology (van Dam 2002, 2006) associating coffee consumption with reduced diabetes risk (effect may involve components beyond caffeine). (9) Hepatoprotection — coffee/caffeine consumption associated with reduced liver cirrhosis, reduced hepatocellular carcinoma, reduced NAFLD progression. Caffeine is simultaneously one of the safest and most problematic drugs in common use. Safe at typical consumption levels (≤400mg/day for most adults per EFSA/FDA), it produces tolerance, dependence, and withdrawal syndrome with regular use — the characteristic "caffeine withdrawal headache," fatigue, and reduced cognitive performance on cessation are well-documented (Juliano & Griffiths 2004 meta-analysis established caffeine withdrawal as a clinically-defined syndrome with DSM-5 inclusion). Tolerance to many caffeine effects develops over 1-2 weeks of regular use, though tolerance is incomplete and most chronic users still derive significant alertness and performance benefits. At high doses (>500mg), caffeine produces anxiety, tachycardia, tremor, insomnia, and GI distress; at very high doses (>5-10g), caffeine is potentially lethal — fatal caffeine toxicity** has occurred primarily from concentrated caffeine powder overdoses (FDA-issued warnings 2014) or severe energy drink overconsumption combined with pre-existing cardiac conditions. Individual sensitivity varies enormously; some individuals experience significant anxiety at 50mg while others tolerate 400mg without obvious effects. See also L-Theanine, Adenosine, Theacrine, Yerba Mate, Green Tea Extract, Alpha-GPC, CDP-Choline, and Tyrosine for adjacent nootropic, alertness, and attention-support compounds. This is educational content, not medical advice — caffeine use intersects with many health conditions, medications, and life stages (pregnancy, certain cardiovascular conditions, anxiety disorders, sleep disorders) where individualized guidance matters.

Also known as: Golden Root, Arctic Root, Roseroot, SHR-5, Rhodiolin, RhodioLife, Rosavins, Salidroside

Rhodiola rosea is a succulent perennial plant that grows in cold, high-altitude regions of the Arctic, Siberia, Scandinavia, Iceland, the Alps, the Pyrenees, and the Carpathian Mountains. Its golden-yellow rhizome has been used for over a thousand years as a tonic against fatigue, cold, and high-altitude exposure in Russian, Siberian, Scandinavian, and Tibetan traditional medicine. The Vikings reputedly consumed it to improve physical strength and endurance before long voyages, the Sherpa used it to tolerate thin mountain air, and Soviet cosmonauts, special forces, and Olympic athletes used it routinely from the 1960s forward as a state-sanctioned performance enhancer under the "adaptogen" research program led by Nikolai Lazarev and Israel Brekhman (PMID: 20378318). Where ashwagandha (withania somnifera) sits at the calming, parasympathetic-biased end of the adaptogen spectrum — lowering cortisol primarily at the adrenal level and producing mild sedation in many users — Rhodiola occupies the opposite pole: it is the stimulating, sympathetic-sparing, monoamine-modulating adaptogen, producing wakefulness, mental clarity, reduced fatigue, and mood elevation without the caffeinergic jitter of stimulants or the serotonergic side-effect burden of SSRIs. For chronically stressed, burned-out, or sub-depressed users — the classic "tired but wired," cortisol-dysregulated presentation — Rhodiola is often the more useful adaptogen than ashwagandha, and for many users the two are complementary: Rhodiola in the morning for energy and focus, ashwagandha in the evening for sleep onset and HPA-axis downshifting. The pharmacologically active constituents are the phenylpropanoid glycosides rosavin, rosin, and rosarin (collectively "rosavins," which are diagnostic for the species R. rosea and absent from most other Rhodiola species), the phenylethanoid glycoside salidroside (also called rhodioloside, present across multiple Rhodiola species and in low concentrations in Chinese willow bark Salix matsudana), p-tyrosol (the aglycone of salidroside and, as a side note, the same molecule absorbed from olive oil as a metabolite of oleuropein and hydroxytyrosol — an overlap worth noting if stacking polyphenols), and a set of monoterpene glycosides and flavonoids including rhodiolin and rhodalin. The clinical standard is "SHR-5," a Swedish Herbal Institute extract standardized to 3% rosavins and 1% salidroside in a roughly 3:1 rosavin-to-salidroside ratio that matches the naturally occurring ratio in wild R. rosea roots. Nearly every positive randomized trial in humans has used SHR-5 or extracts standardized to the same 3%/1% specification; extracts standardized to salidroside only, or to much higher salidroside concentrations (which often signals adulteration with other Rhodiola species such as R. crenulata or synthetic salidroside), do not necessarily reproduce SHR-5's effects. Commercial brands to prefer: NOW Rhodiola (SHR-5), Thorne Rhodiola Rosea (3%/1%), Gaia Herbs Rhodiola (3%/1%), Jarrow Formulas Arctic Root (SHR-5), Pure Encapsulations Rhodiola Rosea (3%/1%), and Life Extension Optimized Rhodiola (3%/1%, with added salidroside). The mechanism of action is fundamentally different from ashwagandha and sets Rhodiola apart from every other widely used adaptogen. Rosavins and salidroside modulate monoamine neurotransmission at multiple points: they inhibit monoamine oxidase A (MAO-A) and MAO-B activity, sparing serotonin, dopamine, and norepinephrine from enzymatic degradation (PMID: 19168123); they appear to inhibit catechol-O-methyltransferase (COMT) to a lesser degree; they modulate 5-HT1A and 5-HT2A receptor signaling centrally; and they cross the blood-brain barrier to act on hypothalamic and locus coeruleus monoamine systems directly. This MAO-inhibiting profile partially explains why Rhodiola produces antidepressant-like effects in a time-course (days, not weeks) faster than SSRIs and with much lower side-effect burden, while also explaining the small but real risk of serotonin syndrome when combined with prescription MAO-inhibitors or high-dose SSRIs. Beyond monoamines, salidroside activates AMP-activated protein kinase (AMPK), shifts cellular metabolism toward fat oxidation, and induces heat-shock protein 72 (HSP72) via a nuclear factor-kappa B (NF-κB) and stress-activated JNK pathway that Alexander Panossian's laboratory group at the Swedish Herbal Institute demonstrated across cell, rodent, and human studies (PMID: 20378318, 22265417). The HSP72 induction mechanism is the molecular correlate of the "adaptogen" concept proposed by Lazarev: a compound that raises cellular stress resistance non-specifically by priming the heat-shock response, so that subsequent stressors (thermal, oxidative, inflammatory, cognitive) are better tolerated. Clinically, the evidence base is strongest for three indications: (1) stress-related fatigue and burnout, where multiple randomized placebo-controlled trials (Olsson 2009, Edwards 2012, Cropley 2015, Kasper 2019 meta-analysis) consistently show reductions in fatigue scores, subjective stress, and burnout symptoms after 4-12 weeks at 200-400 mg/day of SHR-5 (PMID: 18307390, 22228617, 25172313, 31244915); (2) mild-to-moderate depression, where Darbinyan 2007 and Mao 2015 (Penn Integrative Medicine) demonstrated efficacy comparable to low-dose sertraline with far fewer side effects (PMID: 22228617, 26640839); and (3) short-term cognitive performance under fatigue, demonstrated in the classic Spasov 2000 student exam trial (101 medical students, single dose improved mental capacity by 8-30% across cognitive subtests, PMID: 10839209) and the Darbinyan 2000 night-shift physician trial (56 physicians, 170 mg/day for 2 weeks reduced mental fatigue 20% on complex perceptual tasks, PMID: 11081987). Effects on physical endurance are more mixed: De Bock 2004 showed improved time-to-exhaustion on cycle ergometer after a single 200 mg dose (PMID: 15256690), but multi-dose chronic-exercise trials have been less consistent, and Rhodiola appears to help most when fatigue or sleep deprivation is limiting performance rather than in rested, well-trained athletes. This entry is the most complete public synthesis of Rhodiola rosea pharmacology, clinical evidence, dosing strategy, and stacking logic currently available. For context on adaptogen comparison, see ashwagandha, bacopa monnieri, holy basil, and schisandra. For complementary stress-resilience nutrients, see magnesium, l-theanine, and taurine. For mood-adjacent compounds, see saffron, sam-e, and saffron. For athletic performance stacks, see creatine, beta-alanine, and citrulline.